Brolucizumab-early real-world experience: BREW study
Eye (Lond)
.
2021 Apr;35(4):1045-1047.
doi: 10.1038/s41433-020-1111-x.
Epub 2020 Jul 24.
Authors
Ashish Sharma
1
,
Nilesh Kumar
2
,
Nikulaa Parachuri
2
,
Srinivas R Sadda
3
,
Giulia Corradetti
3
,
Jeffrey Heier
4
,
Adam T Chin
4
5
,
David Boyer
6
,
Pouya Dayani
6
,
Sruthi Arepalli
7
,
Peter Kaiser
7
Affiliations
1
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India. drashish79@hotmail.com.
2
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
3
Doheny Eye Institute Los Angeles CA USA, Department of Ophthalmology David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
4
Ophthalmic Consultants of Boston, Boston, MA, USA.
5
Tufts Medical Center, Boston, MA, USA.
6
Retina Vitreous Associates Medical Group, Pasadena, CA, USA.
7
Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
PMID:
32709960
PMCID:
PMC8115627
DOI:
10.1038/s41433-020-1111-x
No abstract available
MeSH terms
Antibodies, Monoclonal, Humanized*
Humans
Receptors, Vascular Endothelial Growth Factor*
Substances
Antibodies, Monoclonal, Humanized
Receptors, Vascular Endothelial Growth Factor
brolucizumab